Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Eagle Pharmaceuticals's enterprise value is $9.9 Mil.
Eagle Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $56.3 Mil. Therefore, Eagle Pharmaceuticals's EV-to-EBITDA for today is 0.18.
The historical rank and industry rank for Eagle Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
EGRX's EV-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 13.56 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Eagle Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Eagle Pharmaceuticals's share price for today is $0.75.
Eagle Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.910.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Eagle Pharmaceuticals EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Eagle Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Eagle Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eagle Pharmaceuticals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eagle Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Eagle Pharmaceuticals's EV-to-EBITDA falls into.
Eagle Pharmaceuticals's current Enterprise Value is $9.9 Mil.
Eagle Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $56.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eagle Pharmaceuticals (EGRX) has a EV-to-EBITDA of 0.18 as of Sep. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Eagle Pharmaceuticals.
Is Eagle Pharmaceuticals' EV-to-EBITDA too high?
Eagle Pharmaceuticals' current EV-to-EBITDA is 0.18. The Drug Manufacturers industry median EV-to-EBITDA is 13.56. Eagle Pharmaceuticals' value of 0.18 is 98.7% below this industry median. Overall, Eagle Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Eagle Pharmaceuticals' EV-to-EBITDA compare to IXHL and RMTI?
Eagle Pharmaceuticals' EV-to-EBITDA of 0.18 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-EBITDA is 13.56. Eagle Pharmaceuticals' value of 0.18 is 98.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.56, based on 726 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eagle Pharmaceuticals's current EV-to-EBITDA of 0.18 is 98.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Eagle Pharmaceuticals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eagle Pharmaceuticals's current EV-to-EBITDA is 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eagle Pharmaceuticals stock overvalued right now?
Eagle Pharmaceuticals (EGRX) has a current EV-to-EBITDA of 0.18. The current EV-to-EBITDA is 0.18 and 98.7% below the Drug Manufacturers industry median of 13.56. Eagle Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Eagle Pharmaceuticals (EGRX), the current EV-to-EBITDA is 0.18 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advance stages of development and is under review for approval by the Food and Drug Administration.
16GF Score
Get the complete analysis for EGRX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EGRX has been successfully added to your 
